
Chinese General Practice ›› 2025, Vol. 28 ›› Issue (12): 1527-1537.DOI: 10.12114/j.issn.1007-9572.2024.0109
Special Issue: 肾脏疾病最新文章合辑
• Evidence-based Medicine • Previous Articles Next Articles
Received:2024-04-18
Revised:2024-07-26
Published:2025-04-20
Online:2025-02-06
Contact:
FENG Zhenzhen
通讯作者:
冯贞贞
作者简介:作者贡献:
王晓雨负责文章的构思与设计、研究资料的收集与整理、论文撰写;冯贞贞负责文章的质量控制与审查,对文章整体负责,监督管理;王军、郭小川负责数据的收集与整理、统计学处理指导;李建生负责论文最终版本审阅修订。
基金资助:CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2024.0109
| 序号 | 检索策略 |
|---|---|
| #1 | Respiratory Distress Syndrome[MeSH Terms] OR Respiratory Distress Syndrome[Title/Abstract] OR Distress Syndrome,Respiratory[Title/Abstract] OR Distress Syndromes,Respiratory[Title/Abstract] OR Respiratory Distress Syndromes[Title/Abstract] OR Syndrome,Respiratory Distress[Title/Abstract] OR Shock Lung[Title/Abstract] OR Lung,Shock[Title/Abstract] OR Respiratory Distress Syndrome,Acute[Title/Abstract] OR Acute Respiratory Distress Syndrome[Title/Abstract] OR ARDS[Title/Abstract] |
| #2 | Acute Kidney Injury[MeSH Terms] OR Acute Kidney Injury[Title/Abstract] OR Acute Kidney Injuries[Title/Abstract] OR Kidney Injuries,Acute[Title/Abstract] OR Kidney Injury,Acute[Title/Abstract] OR Acute Renal Injury[Title/Abstract] OR Acute Renal Injuries[Title/Abstract] OR Renal Injuries,Acute[Title/Abstract] OR Renal Injury,Acute[Title/Abstract] OR Renal Insufficiency,Acute[Title/Abstract] OR Acute Renal Insufficiencies[Title/Abstract] OR Renal Insufficiencies,Acute[Title/Abstract] OR Acute Renal Insufficiency[Title/Abstract] OR Kidney Insufficiency,Acute[Title/Abstract] OR Acute Kidney Insufficiencies[Title/Abstract] OR Kidney Insufficiencies,Acute[Title/Abstract] OR Acute Kidney Insufficiency[Title/Abstract] OR Kidney Failure,Acute[Title/Abstract] OR Acute Kidney Failures[Title/Abstract] OR Kidney Failures,Acute[Title/Abstract] OR Acute Renal Failure[Title/Abstract] OR Acute Renal Failures[Title/Abstract] OR Renal Failures,Acute[Title/Abstract] OR Renal Failure,Acute[Title/Abstract] OR Acute Kidney Failure[Title/Abstract] |
| #3 | Risk Factors[MeSH Terms] OR Risk Factors[Title/Abstract] OR Factor,Risk[Title/Abstract] OR Risk Factor[Title/Abstract] OR Social Risk Factors[Title/Abstract] OR Factor,Social Risk[Title/Abstract] OR Factors,Social Risk[Title/Abstract] OR Risk Factor,Social[Title/Abstract] OR Risk Factors,Social[Title/Abstract] OR Social Risk Factor[Title/Abstract] OR Population at Risk[Title/Abstract] OR Populations at Risk[Title/Abstract] OR Risk Scores[Title/Abstract] OR Risk Score[Title/Abstract] OR Score,Risk[Title/Abstract] OR Risk Factor Scores[Title/Abstract] OR Risk Factor Score[Title/Abstract] OR Score,Risk Factor[Title/Abstract] |
| #4 | #1 AND #2 AND #3 |
Table 1 Search strategies of PubMed
| 序号 | 检索策略 |
|---|---|
| #1 | Respiratory Distress Syndrome[MeSH Terms] OR Respiratory Distress Syndrome[Title/Abstract] OR Distress Syndrome,Respiratory[Title/Abstract] OR Distress Syndromes,Respiratory[Title/Abstract] OR Respiratory Distress Syndromes[Title/Abstract] OR Syndrome,Respiratory Distress[Title/Abstract] OR Shock Lung[Title/Abstract] OR Lung,Shock[Title/Abstract] OR Respiratory Distress Syndrome,Acute[Title/Abstract] OR Acute Respiratory Distress Syndrome[Title/Abstract] OR ARDS[Title/Abstract] |
| #2 | Acute Kidney Injury[MeSH Terms] OR Acute Kidney Injury[Title/Abstract] OR Acute Kidney Injuries[Title/Abstract] OR Kidney Injuries,Acute[Title/Abstract] OR Kidney Injury,Acute[Title/Abstract] OR Acute Renal Injury[Title/Abstract] OR Acute Renal Injuries[Title/Abstract] OR Renal Injuries,Acute[Title/Abstract] OR Renal Injury,Acute[Title/Abstract] OR Renal Insufficiency,Acute[Title/Abstract] OR Acute Renal Insufficiencies[Title/Abstract] OR Renal Insufficiencies,Acute[Title/Abstract] OR Acute Renal Insufficiency[Title/Abstract] OR Kidney Insufficiency,Acute[Title/Abstract] OR Acute Kidney Insufficiencies[Title/Abstract] OR Kidney Insufficiencies,Acute[Title/Abstract] OR Acute Kidney Insufficiency[Title/Abstract] OR Kidney Failure,Acute[Title/Abstract] OR Acute Kidney Failures[Title/Abstract] OR Kidney Failures,Acute[Title/Abstract] OR Acute Renal Failure[Title/Abstract] OR Acute Renal Failures[Title/Abstract] OR Renal Failures,Acute[Title/Abstract] OR Renal Failure,Acute[Title/Abstract] OR Acute Kidney Failure[Title/Abstract] |
| #3 | Risk Factors[MeSH Terms] OR Risk Factors[Title/Abstract] OR Factor,Risk[Title/Abstract] OR Risk Factor[Title/Abstract] OR Social Risk Factors[Title/Abstract] OR Factor,Social Risk[Title/Abstract] OR Factors,Social Risk[Title/Abstract] OR Risk Factor,Social[Title/Abstract] OR Risk Factors,Social[Title/Abstract] OR Social Risk Factor[Title/Abstract] OR Population at Risk[Title/Abstract] OR Populations at Risk[Title/Abstract] OR Risk Scores[Title/Abstract] OR Risk Score[Title/Abstract] OR Score,Risk[Title/Abstract] OR Risk Factor Scores[Title/Abstract] OR Risk Factor Score[Title/Abstract] OR Score,Risk Factor[Title/Abstract] |
| #4 | #1 AND #2 AND #3 |
| 第一作者 | 发表年份(年) | 国家 | 研究类型 | 样本量(例) | ARDS诊断标准 | AKI诊断标准 | AKI发生率(%) | 危险因素 |
|---|---|---|---|---|---|---|---|---|
| SOTO[ | 2012 | 美国 | 前瞻性队列研究 | 751 | 柏林定义 | RIFLE | 61.9 | ④ |
| CRUZ-LAGUNAS[ | 2014 | 墨西哥 | 回顾性病例对照研究 | 32 | 柏林定义 | AKIN | 53.1 | ④ |
| 章兵[ | 2018 | 中国 | 回顾性病例对照研究 | 86 | 柏林定义 | KDIGO | 32.6 | ⑨⑭㉓㉗ |
| 陈大伟[ | 2018 | 中国 | 回顾性病例对照研究 | 837 | 柏林定义 | KDIGO | 53.3 | ②⑲㉓㉕ |
| PANITCHOTE [ | 2019 | 美国 | 回顾性队列研究 | 357 | 柏林定义 | KDIGO | 68.3 | ①⑤⑦⑯ |
| HAN[ | 2019 | 中国 | 回顾性病例对照研究 | 501 | 柏林定义 | KDIGO | 29.5 | ⑦⑧⑩⑪⑬⑳㉚ |
| SHEBL[ | 2020 | 埃及 | 前瞻性队列研究 | 81 | 柏林定义 | KDIGO | 38.3 | ③⑤⑥ |
| 谢晓元[ | 2020 | 中国 | 回顾性病例对照研究 | 105 | 柏林定义 | KDIGO | 55.2 | ⑥㉑ |
| WANG[ | 2021 | 中国 | 回顾性病例对照研究 | 275 | 柏林定义 | KDIGO | 49.5 | ①②⑤⑫⑰㉒ |
| 徐慈[ | 2021 | 中国 | 前瞻性病例对照研究 | 210 | 柏林定义 | KDIGO | 69.4 | ①⑧⑱㉑ |
| 濮雪华[ | 2021 | 中国 | 回顾性病例对照研究 | 120 | 柏林定义 | KDIGO | 47.5 | ⑩⑮⑯ |
| 韩红[ | 2021 | 中国 | 回顾性病例对照研究 | 432 | 柏林定义 | KDIGO | 29.9 | ⑦⑧⑩⑪⑬⑰⑳㉒㉓ |
| CAI[ | 2022 | 中国 | 回顾性病例对照研究 | 193 | 柏林定义 | KDIGO | 53.2 | ⑤⑮㉘ |
| CUI[ | 2022 | 中国 | 前瞻性病例对照研究 | 311 | 柏林定义 | KDIGO | 51.8 | ①⑥⑦⑫㉔㉙ |
| 叶剑滨[ | 2022 | 中国 | 回顾性病例对照研究 | 80 | 柏林定义 | KDIGO | 30 | ⑨⑭⑱㉓㉖ |
| 张宾[ | 2023 | 中国 | 回顾性病例对照研究 | 90 | ARDS诊治指南 | KDIGO | 32.2 | ①⑭⑲㉓ |
| MCNICHOLAS[ | 2023 | 多国 | 前瞻性队列研究 | 1 699 | 柏林定义 | KDIGO | 20.9 | ①②③⑤⑦⑧㉔ |
Table 2 Basic characteristics of included literature
| 第一作者 | 发表年份(年) | 国家 | 研究类型 | 样本量(例) | ARDS诊断标准 | AKI诊断标准 | AKI发生率(%) | 危险因素 |
|---|---|---|---|---|---|---|---|---|
| SOTO[ | 2012 | 美国 | 前瞻性队列研究 | 751 | 柏林定义 | RIFLE | 61.9 | ④ |
| CRUZ-LAGUNAS[ | 2014 | 墨西哥 | 回顾性病例对照研究 | 32 | 柏林定义 | AKIN | 53.1 | ④ |
| 章兵[ | 2018 | 中国 | 回顾性病例对照研究 | 86 | 柏林定义 | KDIGO | 32.6 | ⑨⑭㉓㉗ |
| 陈大伟[ | 2018 | 中国 | 回顾性病例对照研究 | 837 | 柏林定义 | KDIGO | 53.3 | ②⑲㉓㉕ |
| PANITCHOTE [ | 2019 | 美国 | 回顾性队列研究 | 357 | 柏林定义 | KDIGO | 68.3 | ①⑤⑦⑯ |
| HAN[ | 2019 | 中国 | 回顾性病例对照研究 | 501 | 柏林定义 | KDIGO | 29.5 | ⑦⑧⑩⑪⑬⑳㉚ |
| SHEBL[ | 2020 | 埃及 | 前瞻性队列研究 | 81 | 柏林定义 | KDIGO | 38.3 | ③⑤⑥ |
| 谢晓元[ | 2020 | 中国 | 回顾性病例对照研究 | 105 | 柏林定义 | KDIGO | 55.2 | ⑥㉑ |
| WANG[ | 2021 | 中国 | 回顾性病例对照研究 | 275 | 柏林定义 | KDIGO | 49.5 | ①②⑤⑫⑰㉒ |
| 徐慈[ | 2021 | 中国 | 前瞻性病例对照研究 | 210 | 柏林定义 | KDIGO | 69.4 | ①⑧⑱㉑ |
| 濮雪华[ | 2021 | 中国 | 回顾性病例对照研究 | 120 | 柏林定义 | KDIGO | 47.5 | ⑩⑮⑯ |
| 韩红[ | 2021 | 中国 | 回顾性病例对照研究 | 432 | 柏林定义 | KDIGO | 29.9 | ⑦⑧⑩⑪⑬⑰⑳㉒㉓ |
| CAI[ | 2022 | 中国 | 回顾性病例对照研究 | 193 | 柏林定义 | KDIGO | 53.2 | ⑤⑮㉘ |
| CUI[ | 2022 | 中国 | 前瞻性病例对照研究 | 311 | 柏林定义 | KDIGO | 51.8 | ①⑥⑦⑫㉔㉙ |
| 叶剑滨[ | 2022 | 中国 | 回顾性病例对照研究 | 80 | 柏林定义 | KDIGO | 30 | ⑨⑭⑱㉓㉖ |
| 张宾[ | 2023 | 中国 | 回顾性病例对照研究 | 90 | ARDS诊治指南 | KDIGO | 32.2 | ①⑭⑲㉓ |
| MCNICHOLAS[ | 2023 | 多国 | 前瞻性队列研究 | 1 699 | 柏林定义 | KDIGO | 20.9 | ①②③⑤⑦⑧㉔ |
| 纳入研究 | 研究对象选择 | 病例和对照的可比性 | 暴露因素测量 | 总分 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 病例确定是否恰当 | 病例的代表性 | 对照的选择 | 对照的确定 | 暴露因素的确定 | 病例和对照的暴露调查方法 | 无应答率 | |||
| CRUZ[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 章兵[ | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 7 |
| 陈大伟[ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| HAN[ | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 7 |
| 谢晓元[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| WANG[ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| 徐慈[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 濮雪华[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 韩红[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| CAI[ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| CUI[ | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 7 |
| 叶剑滨[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 张宾[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
Table 3 Quality assessment of included literatures(case-control study)
| 纳入研究 | 研究对象选择 | 病例和对照的可比性 | 暴露因素测量 | 总分 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 病例确定是否恰当 | 病例的代表性 | 对照的选择 | 对照的确定 | 暴露因素的确定 | 病例和对照的暴露调查方法 | 无应答率 | |||
| CRUZ[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 章兵[ | 1 | 0 | 0 | 1 | 2 | 1 | 1 | 1 | 7 |
| 陈大伟[ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| HAN[ | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 7 |
| 谢晓元[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| WANG[ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| 徐慈[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 濮雪华[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 韩红[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| CAI[ | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| CUI[ | 1 | 1 | 0 | 1 | 2 | 0 | 1 | 1 | 7 |
| 叶剑滨[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 张宾[ | 1 | 0 | 0 | 1 | 2 | 0 | 1 | 1 | 6 |
| 纳入研究 | 研究对象选择 | 暴露组和非暴露组的可比性 | 暴露因素测量 | 总分 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 暴露组代表性 | 非暴露组的选择 | 暴露因素的确定 | 研究开始前无结局事件发生 | 结局事件的评估 | 随访是否充分 | 随访完整性 | |||
| SOTO[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| PANITCHOTE[ | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 |
| SHEBL[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| MCNICHOLAS[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
Table 4 Quality assessment of included literatures(cohort study)
| 纳入研究 | 研究对象选择 | 暴露组和非暴露组的可比性 | 暴露因素测量 | 总分 | |||||
|---|---|---|---|---|---|---|---|---|---|
| 暴露组代表性 | 非暴露组的选择 | 暴露因素的确定 | 研究开始前无结局事件发生 | 结局事件的评估 | 随访是否充分 | 随访完整性 | |||
| SOTO[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| PANITCHOTE[ | 1 | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 8 |
| SHEBL[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| MCNICHOLAS[ | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| 危险因素 | 纳入研究(项) | 异质性检验 | 效应模型 | OR值 | 95%CI | P值 | |
|---|---|---|---|---|---|---|---|
| I2值(%) | P值 | ||||||
| 一般因素 | |||||||
| 年龄 | 6[ | 71 | 0.004 | 随机 | 1.02 | 1.00~1.03 | 0.007 |
| 年龄(中国) | 4[ | 73 | 0.010 | 随机 | 1.04 | 1.00~1.09 | 0.040 |
| 男性 | 3[ | 72 | 0.030 | 随机 | 1.17 | 0.82~1.67 | 0.390 |
| 男性(中国) | 2[ | 51 | 0.150 | 随机 | 1.35 | 0.86~2.13 | 0.190 |
| BMI | 2[ | 88 | 0.003 | 随机 | 1.27 | 0.77~2.09 | 0.350 |
| 肥胖 | 2[ | 56 | 0.130 | 随机 | 5.88 | 0.51~68.28 | 0.160 |
| 整体评估 | |||||||
| SOFA评分 | 5[ | 75 | 0.003 | 随机 | 1.17 | 1.05~1.30 | 0.004 |
| SOFA评分(中国) | 2[ | 0 | 0.390 | 固定 | 1.09 | 1.01~1.18 | 0.030 |
| APACHEⅡ评分 | 3[ | 79 | 0.008 | 随机 | 1.20 | 0.99~1.46 | 0.060 |
| APACHEⅡ评分(中国) | 2[ | 83 | 0.020 | 随机 | 1.28 | 0.81~2.02 | 0.290 |
| 疾病因素 | |||||||
| 糖尿病 | 5[ | 51 | 0.080 | 随机 | 1.40 | 1.09~1.80 | 0.008 |
| 糖尿病(中国) | 3[ | 0 | 0.650 | 固定 | 1.81 | 1.26~2.59 | 0.001 |
| 高血压 | 4[ | 75 | 0.007 | 随机 | 1.56 | 1.26~1.93 | <0.001 |
| 高血压(中国) | 3[ | 0 | 0.970 | 固定 | 1.70 | 1.62~1.79 | <0.001 |
| 心力衰竭 | 2[ | 76 | 0.040 | 随机 | 4.49 | 0.58~34.70 | 0.150 |
| 意识障碍 | 3[ | 84 | 0.002 | 随机 | 1.83 | 0.88~3.84 | 0.110 |
| 心房颤动 | 2[ | 0 | 0.710 | 固定 | 1.76 | 1.09~2.85 | 0.020 |
| 慢性肾病 | 2[ | 0 | 0.970 | 固定 | 10.31 | 3.30~32.19 | <0.001 |
| 胸腔积液 | 2[ | 0 | 0.750 | 固定 | 1.16 | 0.81~1.65 | 0.410 |
| 实验室指标 | |||||||
| 氧合指数 | 3[ | 90 | <0.001 | 随机 | 4.30 | 0.69~26.77 | 0.120 |
| PCT | 2[ | 82 | 0.020 | 随机 | 1.08 | 0.95~1.23 | 0.230 |
| 动脉血pH值 | 2[ | 0 | 0.390 | 固定 | 0.83 | 0.75~0.92 | 0.000 6 |
| NLR | 2[ | 59 | 0.120 | 随机 | 1.02 | 1.00~1.05 | 0.030 |
| Ang-2 | 2[ | 41 | 0.190 | 固定 | 1.84 | 1.73~1.95 | <0.001 |
| WBC | 2[ | 69 | 0.070 | 随机 | 1.56 | 0.51~4.80 | 0.440 |
| AST>40 U/L | 2[ | 0 | 0.650 | 固定 | 2.27 | 1.56~3.31 | <0.001 |
| GFR | 2[ | 0 | 0.530 | 固定 | 0.92 | 0.86~0.99 | 0.020 |
| 血浆白蛋白 | 2[ | 83 | 0.020 | 随机 | 1.07 | 0.97~1.17 | 0.170 |
| 治疗因素 | |||||||
| 机械通气 | 5[ | 44 | 0.130 | 固定 | 2.53 | 1.96~3.26 | <0.001 |
| ECMO | 2[ | 0 | 0.440 | 固定 | 1.81 | 1.43~2.28 | <0.001 |
Table 5 Meta-analysis of risk factors for AKI in ARDS
| 危险因素 | 纳入研究(项) | 异质性检验 | 效应模型 | OR值 | 95%CI | P值 | |
|---|---|---|---|---|---|---|---|
| I2值(%) | P值 | ||||||
| 一般因素 | |||||||
| 年龄 | 6[ | 71 | 0.004 | 随机 | 1.02 | 1.00~1.03 | 0.007 |
| 年龄(中国) | 4[ | 73 | 0.010 | 随机 | 1.04 | 1.00~1.09 | 0.040 |
| 男性 | 3[ | 72 | 0.030 | 随机 | 1.17 | 0.82~1.67 | 0.390 |
| 男性(中国) | 2[ | 51 | 0.150 | 随机 | 1.35 | 0.86~2.13 | 0.190 |
| BMI | 2[ | 88 | 0.003 | 随机 | 1.27 | 0.77~2.09 | 0.350 |
| 肥胖 | 2[ | 56 | 0.130 | 随机 | 5.88 | 0.51~68.28 | 0.160 |
| 整体评估 | |||||||
| SOFA评分 | 5[ | 75 | 0.003 | 随机 | 1.17 | 1.05~1.30 | 0.004 |
| SOFA评分(中国) | 2[ | 0 | 0.390 | 固定 | 1.09 | 1.01~1.18 | 0.030 |
| APACHEⅡ评分 | 3[ | 79 | 0.008 | 随机 | 1.20 | 0.99~1.46 | 0.060 |
| APACHEⅡ评分(中国) | 2[ | 83 | 0.020 | 随机 | 1.28 | 0.81~2.02 | 0.290 |
| 疾病因素 | |||||||
| 糖尿病 | 5[ | 51 | 0.080 | 随机 | 1.40 | 1.09~1.80 | 0.008 |
| 糖尿病(中国) | 3[ | 0 | 0.650 | 固定 | 1.81 | 1.26~2.59 | 0.001 |
| 高血压 | 4[ | 75 | 0.007 | 随机 | 1.56 | 1.26~1.93 | <0.001 |
| 高血压(中国) | 3[ | 0 | 0.970 | 固定 | 1.70 | 1.62~1.79 | <0.001 |
| 心力衰竭 | 2[ | 76 | 0.040 | 随机 | 4.49 | 0.58~34.70 | 0.150 |
| 意识障碍 | 3[ | 84 | 0.002 | 随机 | 1.83 | 0.88~3.84 | 0.110 |
| 心房颤动 | 2[ | 0 | 0.710 | 固定 | 1.76 | 1.09~2.85 | 0.020 |
| 慢性肾病 | 2[ | 0 | 0.970 | 固定 | 10.31 | 3.30~32.19 | <0.001 |
| 胸腔积液 | 2[ | 0 | 0.750 | 固定 | 1.16 | 0.81~1.65 | 0.410 |
| 实验室指标 | |||||||
| 氧合指数 | 3[ | 90 | <0.001 | 随机 | 4.30 | 0.69~26.77 | 0.120 |
| PCT | 2[ | 82 | 0.020 | 随机 | 1.08 | 0.95~1.23 | 0.230 |
| 动脉血pH值 | 2[ | 0 | 0.390 | 固定 | 0.83 | 0.75~0.92 | 0.000 6 |
| NLR | 2[ | 59 | 0.120 | 随机 | 1.02 | 1.00~1.05 | 0.030 |
| Ang-2 | 2[ | 41 | 0.190 | 固定 | 1.84 | 1.73~1.95 | <0.001 |
| WBC | 2[ | 69 | 0.070 | 随机 | 1.56 | 0.51~4.80 | 0.440 |
| AST>40 U/L | 2[ | 0 | 0.650 | 固定 | 2.27 | 1.56~3.31 | <0.001 |
| GFR | 2[ | 0 | 0.530 | 固定 | 0.92 | 0.86~0.99 | 0.020 |
| 血浆白蛋白 | 2[ | 83 | 0.020 | 随机 | 1.07 | 0.97~1.17 | 0.170 |
| 治疗因素 | |||||||
| 机械通气 | 5[ | 44 | 0.130 | 固定 | 2.53 | 1.96~3.26 | <0.001 |
| ECMO | 2[ | 0 | 0.440 | 固定 | 1.81 | 1.43~2.28 | <0.001 |
| [1] |
冯云爱,李海潮. 急性呼吸窘迫综合征的定义演变、争议及本质探讨[J]. 中华结核和呼吸杂志,2024,47(1):87-90. DOI:10.3760/cma.j.cn112147-20230713-00005.
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] | |
| [8] |
|
| [9] |
中华医学会重症医学分会. 急性肺损伤/急性呼吸窘迫综合征诊断和治疗指南(2006)[J]. 中国危重病急救医学,2006,18(12):706-710. DOI:10.3760/j.issn:1003-0603.2006.12.002.
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
陈大伟. 社区获得性肺炎相关的ARDS患者发生AKI的危险因素及预后分析[D]. 南京:南京医科大学,2018.
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
谢晓元,马金兰,巴应贵. 老年急性呼吸窘迫综合征患者并发急性肾损伤危险因素及预后[J]. 中国老年学杂志,2020,40(19):4157-4161. DOI:10.3969/j.issn.1005-9202.2020.19.041.
|
| [19] |
|
| [20] |
徐慈,李亚茜,项涛,等. 血浆FGF23及Ang2水平预测急性呼吸窘迫综合征患者并发急性肾损伤的价值分析[J]. 疑难病杂志,2021,20(11):1126-1130. DOI:10.3969/j.issn.1671-6450.2021.11.010.
|
| [21] |
濮雪华,汤梦南,胡海涛,等. 有创通气的急性呼吸窘迫患者发生急性肾损伤的危险因素分析[J]. 中华急诊医学杂志,2021,30(12):1489-1493. DOI:10.3760/cma.j.issn.1671-0282.2021.12.014.
|
| [22] |
韩红,刘张波,何传梅,等. 老年呼吸窘迫综合征患者相关急性肾损伤危险因素分析[J]. 中华老年医学杂志,2021,40(10):1280-1285. DOI:10.3760/cma.j.issn.0254-9026.2021.10.013.
|
| [23] |
|
| [24] |
|
| [25] |
叶剑滨,叶剑清,钟超. 血管生成素2、C反应蛋白与急性呼吸窘迫综合征并发急性肾损伤的相关性分析[J]. 大医生,2022,7(9):12-15.
|
| [26] |
张宾,代洪娜,李洁,等. 急性呼吸窘迫综合征合并急性肾损伤危险因素的回顾性研究[J]. 医药论坛杂志,2023,44(16):13-16.
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [1] | LIN Zehua, ZHANG Lan, DAI Shanshan, WEI Yuanyuan, LI Xingli, MA Yingchun. Evaluation and Comparison of Multidimensional Functional Disability in Geriatric Comorbidities and Comorbid Acute Kidney Injury [J]. Chinese General Practice, 2026, 29(32): 4777-4782. |
| [2] | HE Yang, YANG Rong, SHEN Can, YI Shanye, LIU Lidi, ZHAO Qian, WAN Zhi, LIAO Xiaoyang. Progress in Research on the Trajectory of Frailty and Its Influencing Factors [J]. Chinese General Practice, 2026, 29(30): 4372-4378. |
| [3] | GUO Zhihong, CHEN Yingying, LIU Dewu. Efficacy and Safety of Antibiotic Bone Cement Combined with Vacuum Sealing Drainage for Diabetic Foot: a Meta-analysis [J]. Chinese General Practice, 2026, 29(30): 4503-4512. |
| [4] | ZHAO Congjuan, JIN Tiantian, LIANG Jie, WANG Beining, GAO Yan. Comparative Effectiveness of GLP-1 Receptor Agonists on Patients with Diabetic Kidney Disease: a Network Meta-analysis [J]. Chinese General Practice, 2026, 29(29): 4326-4336. |
| [5] | JIANG Yanlin, WANG Zhe, ZHAI Rui, ZHANG Mengjie, CHEN Xi, WANG Junhong. Screening Optimal Traditional Chinese Medicine Compound Formulas for ADHD Treatment: a Study Integrating Network Meta-analysis and Entropy-weighted TOPSIS Method [J]. Chinese General Practice, 2026, 29(27): 3985-3994. |
| [6] | LIU Zhenyu, WANG Wendong, YAO Qing, WANG Jiangmin, CAO Wendong. Analysis of Prevalence and Influencing Factors of Cardiovascular-kidney-metabolic Syndrome among Adults in Haidian District, Beijing [J]. Chinese General Practice, 2026, 29(27): 3969-3975. |
| [7] | ZHUANG Mingnan, YAN Henghao, XIAO Ningkun, YIN Mingyue, FAN Zhiwei, LIU Chaohui, ZOU Xintong, ZHOU Yuehua, BI Zhiyuan, DENG Hengzhi, WU Bitai, SONG Zhiquan, SHI Donglin. Effects of Interval and Continuous Training on Cognitive Function in Healthy Adults: a Systematic Review and Three-level Meta-analysis [J]. Chinese General Practice, 2026, 29(26): 3816-3828. |
| [8] | ZHANG Xuechao, QI Qi, WU Xinyu, HAN Quanle, LI Lei, DENG Jie, LI Cangtuo, YUE Bocheng, WU Shouling, LI Kangbo. Association between the Atherogenic Index of Plasma and New-onset Chronic Kidney Disease [J]. Chinese General Practice, 2026, 29(24): 3440-3446. |
| [9] | LI Xueni, LIU Gejing, LIU Yongming. Efficacy and Safety of Semaglutide in Patients with Heart Failure: a Meta-Analysis [J]. Chinese General Practice, 2026, 29(24): 3509-3519. |
| [10] | WANG Rui, LUO Shuoming, YANG Liang, WANG Peng, ZHAO Yang, WANG Qi, ZHOU Zhiguang. Diabetes Prevalence among Older Adults in China: a Systematic Review and Meta-analysis [J]. Chinese General Practice, 2026, 29(24): 3500-3508. |
| [11] | PEI Ruqing, ZHOU Yuqiu, ZHANG Siyu, LIU Xijun. Meta-analysis of Influencing Factors of Relapse in Chinese Patients with Schizophrenia [J]. Chinese General Practice, 2026, 29(23): 3359-3370. |
| [12] | WANG Xinliang, ZOU Nannan, CHEN Nana, WANG Xin. Analysis of Clinical Characteristics and Prognostic Risk Factors in Patients with Pulmonary Mucormycosis Complicated with Diabetes Mellitus [J]. Chinese General Practice, 2026, 29(22): 3154-3161. |
| [13] | FENG Yuxi, WANG Jinjin, CAI Yi, ZHU Runzhi, ZHU Qin. Research Progress on Protein Lactylation in Kidney Diseases [J]. Chinese General Practice, 2026, 29(21): 3056-3063. |
| [14] | AN Yanhong, WANG Shidong, LI Xiaoran, GUO Jiayang, WANG Zhe, SHA Peilin, MENG Yijun, LI Xiaoxuan, SHI Xue, YU Zexing, XIAO Yonghua. Study on Risk Factors and Nomogram Prediction Model for Diabetic Kidney Disease: Based on Contrast-enhanced Ultrasound Technology [J]. Chinese General Practice, 2026, 29(21): 2995-3003. |
| [15] | SONG Zhenzhen, CHEN Yang, WANG Jiwen, LIU Huishan, SHEN Simeng, SUN Ying, CHEN Xing. Study of Maternal Risk Factors Associated with Neonatal Asphyxia in Late Preterm and Term Infants [J]. Chinese General Practice, 2026, 29(20): 2874-2878. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||